เดือน: สิงหาคม 2024

Toyota City, Japan, Aug 23, 2024 - (JCN Newswire via SeaPRwire.com) - TOYOTA GAZOO Racing aims to maintain momentum in its challenge for FIA World Endurance Championship (WEC) titles when the 2024 season moves to Austin, Texas for the Lone Star Le Mans at the Circuit of the Americas on 1 September.An accomplished victory in São Paulo in the last round sees TOYOTA GAZOO Racing just four points behind leaders Porsche in a hard-fought battle for the manufacturers’ World Championship heading to the United States for round six of the season.Mike Conway, Kamui Kobayashi and Nyck de Vries showed the pace of their #7 GR010 HYBRID by earning pole position and leading the early stages in São Paulo before a technical issue saw them finish fourth. They will challenge for their second victory of the year in Austin, where the team has yet to win in six attempts.Out front in Brazil, reigning World Champions Sébastien Buemi, Brendon Hartley and Ryo Hirakawa won for the first time this season in their #8 GR010 HYBRID. That victory ensured Sébastien, who is tied with Brendon with the most titles on four, set a new record of 25 WEC race wins.The heat of a Texan summer awaits the team and drivers at the 5.513km Circuit of the Americas in the six-hour Lone Star Le Mans race, which returns to the WEC calendar for the first time since 2020.TOYOTA GAZOO Racing has a best finish of second place in its six visits so far to Texas, achieved in 2013 and 2020, while Brendon has won the race three times. Although the team has yet to taste victory in Austin, it has achieved two wins in the United States, at Sebring in 2019 and 2023.The Circuit of the Americas is, like Interlagos last time out, an anti-clockwise track, characterised by the steep hill up to turn one followed by a sequence of sweeping, fast corners which create a spectacular opening sector.The team made an early start to its preparations for next week’s race with a three-day test in Austin at the end of July. Preparations step up a gear when track action starts on Friday 30 August with three hours of free practice in the afternoon split over two sessions. After a one-hour final practice on Saturday morning, the starting order will be decided during qualifying and Hyperpole, starting at 3.40pm local time (10.40pm CEST). The seventh Lone Star Le Mans race starts at 1pm (8pm CEST) on Sunday 1 September.For more information, visit https://toyotagazooracing.com/wec/release/2024/rd06-preview/. Copyright 2024 JCN Newswire via SeaPRwire.com.

ZURICH, SWITZERLAND, Aug 23, 2024 - (JCN Newswire via SeaPRwire.com) - Hitachi Energy, a global technology leader, is launching a new technology that will tackle emissions of sulfur hexafluoride (SF6), 80 percent of which come from the power sector.Sulfur hexafluoride (SF6) is widely used in switchgear, the critical components protecting our power grids anddelivering the energy transition in a time of extraordinary grid expansion. It is 24,300 times more climate-hostile than CO2 and remains in the atmosphere for over a thousand years – much longer than CO2, which lasts less than 200years. Overall, it makes up 220 million tons of CO2 equivalent or 0.6 percent of global emissions. To put it intoperspective, this exceeds the equivalent of 50 typical coal power plants.While high industry standards mean that leaks are minor and accidental releases of SF6 rare, private stakeholders and regulators alike are reluctant to continue using SF6, a gas they see as a significant environmental threat and liability.To help the power sector tackle this huge problem, Hitachi Energy has launched the world's highest voltage SF6-freeswitchgear – the EconiQTM 550 kV circuit breaker that can be used in gas-insulated switchgear (GIS) or dead tankbreakers (DTB) and the EconiQ 420 kV Live Tank Breaker (LTA).This equipment will replace SF6 switchgear around the world, including in China, which is the source of 57 percent of the global SF6 emissions. Each new 550 kV GIS substation using EconiQ eliminates the carbon equivalent of 170 fully booked jumbo jets flying from Paris to New York while retaining the size, performance, and reliability levels oftraditional switchgear.Markus Heimbach, Executive Vice President and Managing Director of the High Voltage Products business unit at Hitachi Energy said: "It's hard to overstate the critical role that this little-known gas plays in keeping the lights on – it has been as central to building our modern world as steel and concrete.""This makes SF6 exceptionally challenging to phase out. The industry can only overcome the dual challenges of strict SF6 regulations and rising transmission demands with solutions that eliminate this gas without sacrificing size or performance. Our new EconiQ technology is the first to meet this critical need. Hitachi Energy is the first to have come up with sustainable products for this voltage level, where the largest portion of SF6 is used.”"As the world shifts to a sustainable energy future, so must power systems. With switchgear typically in service for 40years, it's important to act fast, as decisions taken today will determine the success of Net Zero in 2050."As the industry's only SF6-free solution for these voltage ratings, Hitachi Energy's new offerings maintain the samefootprint, dimensions, compatibility, lifespan, safety, reliability, and efficiency as traditional SF6 equipment. This allowsutilities and operators to plan SF6 phaseout roadmaps, enabling them to swap components, retrofit or replace oldswitchgear and install new ones with no new construction requirements, and with only minor technical changes and minor new training needs.Around 1,300 tons of SF6 is used in the UK's network of substations alone, with more than 10,000 tons used in the European Union. This leaves power grid operators to focus on two pressing challenges: delivering the energy transition and addressing climate change. The former demands a rapid expansion of grid infrastructure like switchgear, while the latter necessitates an urgent phaseout of SF6.The European Union has already implemented a strict phaseout and banned SF6 in medium and high-voltage switchgear by 2030 and 2032, respectively. The UK and USA are preparing similar regulations.SF6-free switchgear in actionBoth new EconiQ products have pilot orders confirmed and form part of ambitious climate commitments from utilities, demonstrating the need for SF6-free products at this voltage.TenneT, the Dutch-German transmission system operator responsible for over 25,000 km of high-voltage lines and cables, has placed an order for Hitachi Energy's new EconiQ 420 kV LTA. TenneT plans to use the new infrastructureto support its ambition of reducing grid losses, along with the climate impact of its own operations.SSEN Transmission, one of Europe’s fastest growing network businesses with ambitious plans to invest £20 billion inthe north of Scotland electricity transmission network to support UK and Scottish energy security and clean powertargets, has placed an order for the new generation EconiQ 420 kV LTA. The new order supports the company's strategy to no longer install equipment containing SF6 wherever viable. These are part of the company’s wider decarbonization ambitions, having been the world’s first transmission network accredited by the Science Based Target initiative for its carbon reduction targets, which are consistent with Net Zero pathways.Rob McDonald, Managing Director of SSEN Transmission, said: “We are delighted to collaborate with Hitachi Energyand order some of the world's first SF6-free 420 kV AIS circuit breakers, which is a testament to our position as a leader in the adoption of SF6 alternatives. The use of the technology is a key enabler to ensure we meet our ambitious grid expansions plans for 2030 and beyond, as well as our science-based carbon reduction target. The equipment will be used for a substation upgrade project in the north of Scotland which will reinforce the local network and allow for the connection of several onshore wind farms, contributing to UK Net Zero targets."In North America, where the 550 kV voltage is common, two customers have also placed orders for the new EconiQ 550 kV DTB, Hydro One and Wesco.Hydro One Limited, through its wholly owned subsidiaries, is Ontario's largest electricity transmission anddistribution provider with approximately 1.5 million valued customers,approximately $32.8 billion in assets as of December 31, 2023, and annual revenues in 2023 of approximately $7.8 billion. Hydro One expects this partnership to contribute to its climate change mitigation initiatives to achieve net-zero GHG emissions by 2050.Wesco is based in Pittsburgh, Pennsylvania, and has remained committed to powering progress around the world since the rise of electrification in the early 1900s to the digital revolution of today, delivering ingenuity and expertise to approximately 150,000 customers worldwide. The EconiQ eco-efficient 550 kV dead tank breaker will enable Wesco to fulfill its customers ambitious sustainability goals for 2030 and beyond.Jim Cameron, Wesco’s Executive Vice President and General Manager of its Utility and Broadband Solutions business unit, emphasized Wesco’s dual commitment to sustainability. He stated, “We are dedicated to minimizing the environmental impact of our operations and assisting our customers in achieving their sustainability goals. Thegroundbreaking technology of Hitachi Energy’s EconiQ 550 breaker, which reduces SF6 emissions, aligns perfectly with our corporate sustainability charter. We are proud to be part of the first installation in North America.”About Hitachi EnergyHitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We are advancing the world’s energy system to be more sustainable, flexible and secure and we collaborate with customers and partners to enable a sustainable energy future – for today’s generations and those to come. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries, serving customers in utility, industry, transportation, data centers and infrastructure sectors. With innovative technologies and services including the integration of more than 150 gigawatts of HVDC links into the power system, we help make the energy value chain more efficient, making electricity more accessible to all. Together with stakeholders across sectors and geographies, we enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. Headquartered in Switzerland, we employ around 45,000 people in 90 countries and generate business volumes of around $13 billion USD.www.hitachienergy.com www.linkedin.com/company/hitachienergyhttps://twitter.com/HitachiEnergyAbout Hitachi, Ltd.Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of "Digital Systems & Services" – supporting our customers' digital transformation; "Green Energy & Mobility" – contributing to a decarbonized society through energy and railwaysystems, and "Connective Industries" – connecting products through digital technology to provide solutions in variousindustries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company's revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiaries and approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company's website at www.hitachi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Hitachi High-Tech Corporation announced today the global launch of TM4000PlusIII and TM4000III Tabletop Microscopes equipped with support features for automation and stable operation.The TM Series shrinks the electron microscope to a size capable of being mounted on a tabletop. Thanks to theircompact size and ease of installation, desktop microscopes are widely used not only for R&D, but also in quality controlat manufacturing sites, science education at schools, and other purposes. In manufacturing environments in particular, there is a need to increase the efficiency of observation tasks and streamline operations so that even users with limited expertise can easily observe a large number of samples.The TM4000PlusIII is equipped with automation support features that enable users to create recipes for numerous conditions. Recipes can control functions such as stage position adjustment and magnification, which previouslyneeded to be manually configured every time for each sample. In addition, they come equipped with maintenance features designed to facilitate consistent observation. One such function is a monitoring system that checks the condition of the tungsten filament* and graphically reports its condition. Since tungsten filaments require regular replacement, this function allows users to track the filament lifetime and plan ahead with maintenance tasks to allow for smooth and consistent operation of the tool.*Tungsten filaments: A single part used in the electron gun of an electron microscope. They are typically made by bending a thin wire made of tungsten (element symbol: W), which is a highly heat-resistant metal, into a hairpin-like shape and connecting it to an electrode. The tungsten filament emits an electron beam when heated.Product Development BackgroundBecause the TM Series makes it possible to conduct high-precision observation and analysis, even when installationspace is limited, it has come to be a critical tool during the development and quality control of new materials. Recently, the TM Series has contributed to conserving the environment and maintaining people’s health by being used to develop environmentally friendly materials and their manufacturing processes, as well as analyze harmful substances in the atmosphere. In manufacturing environments, the trend of decreasing feature size and stricter quality control has led to an increase in the number of SEM users. However, not all new users have specialized knowledge and operatingskills. Amidst this trend, we developed the TM4000PlusIII and TM4000III to have this sought-after optimization and simplification of observation tasks for the purposes of enabling the acquisition of high-precision data without any variability, regardless of who is operating the microscope or their level of expertise.Key Features1. Making Tasks More EfficientThe automation support feature with the TM4000PlusIII allows for observation procedures, such as stage movement, magnification changes, and imaging, to be saved as recipes. They can then be executed to run automatically with a single click. This makes operations more efficient and standardizes techniques among users. This is beneficial for those looking to automate routine tasks and for users who are concerned about having to manually configure observation conditions.The TM4000PlusIII also features a setting for high-current mode which enables faster operations due to the increasedobservation signal. For example, in particle analysis a large number of measurement points are required which can bevery time consuming to collect. The high-current function shortens measurement time for each location while reducing the overall time involved in such tasks.2. Plan Ahead with the Filament Monitoring FunctionThe microscopes come equipped with new support features to ensure they can be used with peace of mind at all times. One example is the filament indicator feature, which allows users to track the filament life on screen, preventinginstances of observations being interrupted due to filament replacements occurring mid-observation.3. Ideal for Educational PurposesThe TM Series is equipped with low-vacuum and high-sensitivity backscattered electron detectors, which eliminate the need for complicated pretreatment processes. This makes it possible to conduct observations on a variety of sampleswith ease, enabling the TM Series to be utilized in educational settings.Additionally, as digital skill development becomes a critical subject in educational settings, the TM4000PlusIII allowusers to experience and learn important programming concepts such as “sequential execution,” “repetition,” and “conditional branching” via the automation support features.The TM4000PlusIII and TM4000III will be exhibited at JASIS 2024 at the Makuhari Messe International ExhibitionHalls in Chiba, Japan, from September 4 through September 6, 2024.Hitachi High-Tech aims to ship a target total of 6,000 TM Series units across the global market as quickly as possible to contribute to manufacturing worldwide. Hitachi High-Tech will continue to refine our core analysis technologies, and provide measurement and inspection solutions that support R&D and quality control operations in a wide range of fields, in order to help improve people's QoL (Quality of Life) and to resolve social issues related to the environment, resilience, and security and safety.About Hitachi High-TechHitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, includingmanufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Also, we provide high value-added solutions in industrial fields such as mobility, connected, environment and energy, etc. Through business based on our core Observation, Measurement and Analysis technologies, we will contribute to the realization of a sustainable society by solving social issues.The company's consolidated revenues for FY2023 were approx. JPY 670.4 billion. For further information, visit www.hitachi-hightech.com/global/en/Business Contact:Takeshi KamimuraGlobal Sales Planning Dept.Beam Technology & Analytical Systems Business Div., Core Technology & Solutions Business GroupHitachi High-Tech CorporationEmail: takeshi.kamimura.jj@hitachi-hightech.com Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatmentof mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein Eε4 (ApoE ε4)* heterozygotes or non-carriers.1 Lecanemab becomes the first treatment for early AD (MCI and mild dementia due to AD)2 that targets an underlying cause of the disease, to be authorized in a country in Europe.1Lecanemab selectively binds to Aβ aggregate species, with preferential activity for toxic Aβ protofibrils** (as well as fibrils, which are a major component of Aβ plaques).2,3,4 It binds to these aggregate Aβ species to neutralize and clear them from the brain.2,3,4The approval was primarily based on Phase 3 data from Eisai’s global, placebo-controlled, double-blind, parallel-group, randomized Clarity AD clinical trial, in which the medicine met its primary endpoint (change from baseline in the Clinical Dementia Rating Sum of Boxes [CDR-SB]† at 18 months) and all key secondary endpoints with statistically significant results.2 Inthe indicated population in Great Britain, the most common adverse reactions were infusion-related reaction, amyloid-related imaging abnormalities with hemorrhage (small spots of bleeding) (ARIA-H)‡, fall, headache and amyloid-related imaging abnormalities with cerebral edema (build-up of fluid) (ARIA-E)‡‡.1In the United Kingdom, it is estimated that 982,000 people are living with dementia,5 and AD is the cause in 60-70% of people with dementia.6 These numbers are expected to rise, as the population ages.5,6Eisai is working collaboratively with the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the National Health Service (NHS) to make this medicine available to eligible people living with early AD as soon as possible.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In Great Britain, Eisai and Biogen will co-promote the medicine, with Eisai distributing the product as the Marketing Authorization holder.*Apolipoprotein E is a protein involved in the metabolism of fats in humans. It is implicated in AD.**Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms. 7 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.8†CDR-SB is a commonly used diagnostic tool, which can help to stage dementia due to AD.9 It is a global cognitive and functional scale that measures six domains of functioning, including memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.9‡ARIA-H: amyloid-related imaging abnormalities with hemorrhage (microhemorrhages, and superficial siderosis).‡‡ARIA-E: amyloid-related imaging abnormalities with oedema (edema/effusion).More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 7974-879-419Emea-comms@eisai.netBiogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comEisai Inc. (U.S.)Libby Holman1-201-753-1945Libby_Holman@eisai.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department TEL: +81 (0) 3-3817-5122Biogen Inc.Chuck Triano+ 1-781-464-2442IR@biogen.comAbout lecanemab (Leqembi®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).2,3Lecanemab’s approval in Great Britain was primarily based on Phase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 Clarity AD was a Phase 3global, placebo-controlled, double-blind, parallel-group, randomized study in 1,795 patients with early AD (MCI or milddementia due to AD, with confirmedpresence of amyloid pathology), of which 1,521 were in the indicated population in the label in Great Britain (ApoE ε4heterozygotes or non-carriers).1 Of the total number of patients randomized 31% were non-carriers, 53% were heterozygotes and 16% were homozygotes.1 The treatment group was administered lecanemab 10 mg/kg bi-weekly, with participants allocated in a 1:1 ratio to receive either placebo or lecanemab for 18 months.1The primary endpoint was the global cognitive and functional scale, CDR-SB.1 In the Clarity AD clinical trial, treatment with lecanemab, in the indicated population in Great Britain (ApoE ε4 heterozygotes or non-carriers), reduced clinical decline on CDR-SB by 33% at 18 months compared to placebo.1 The mean CDR-SB score at baseline was approximately 3.2 in both groups.1 The adjusted least-squares mean change from baseline at 18 months was 1.15 with lecanemab and 1.73 with placebo(difference, −0.58; 95% confidence interval [CI], −0.81 to −0.34; P<0.00001).1 CDR-SB is a global cognitive and functional scale that measures six domains of functioning, including memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.9In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted 39% less decline compared to placebo at 18 months.1 The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADLscore was −3.5 in the lecanemab group and −5.7 in the placebo group (difference, 2.2; 95% CI, 1.3 to 3.1; P<0.00001).1 The ADCS-MCI-ADL assesses the ability ofpatients to function independently, including being able to dress, feed themselves and participate in community activities.In the indicated population (ApoE ε4 heterozygotes or non-carriers), the most common adverse reactions were infusion-related reaction (26%), ARIA-H (13%), fall (11%), headache (11%) and ARIA-E (9%).1Lecanemab is licensed in the U.S., 10 Japan, 11 China, 12 South Korea, 13 Hong Kong, 14 Israel, 15 the United Arab Emirates16 and Great Britain1 and marketed in the U.S., Japan and China. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union.This medicine is subject to additional monitoring. This will allow quick identification of new safety information.About NHS, NICE and SMCThe NHS is a public healthcare system with the principle of providing free medical services to citizens. The NICE and the SMC are independent bodies that carry out assessments on the status of all newly licensed medicines, all new formulations of existing medicines and new indications for established products regarding their health benefits and price justification as advisory boards to the NHS about whether or not a newly licensed drug should be accepted for use under national health insurance.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisaiserves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on theantibody back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities,manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us onX, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com.Follow Biogen on social media – Facebook, LinkedIn, X, YouTube. The website and social media channels are intended for audiences outside of the UK and Europe.Biogen Safe HarborThis news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; thetreatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small numberof research and development programs result in commercialization of a product. Results in early-stage clinical studies may notbe indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatoryauthorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates; including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of the medicine; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertaintiesrelating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results ofoperationsand financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ fromBiogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the riskfactors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securitiesand Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake anyobligation to publicly update any forward-looking statements.(1) Lecanemab Great Britain Summary of Product Characteristics(2) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine.2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948.(3) Johannesson, M., et al. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Molecular and Cellular Neuroscience. 2024;130:103949. https://doi.org/10.1016/j.mcn.2024.103949.(4) Sehlin, D., et al. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2):e32014. https://doi.org/10.1371/journal.pone.0032014.(5) Alzheimer’s Society. 2024. The economic impact of dementia. Available at: https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-scale-impact-numbers. Last accessed: August 2024.(6) World Health Organization. 2023. Dementia. Available at: https://www.who.int/news-room/fact- sheets/detail/dementia. Last accessed: August 2024(7) Amin, L., Harris, D.A. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxicoligomers. Nature Communications. 2021;12:3451. doi:10.1038/s41467-021-23507-z. (8) Ono, K., Tsuji, M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. International Journal of Molecular Sciences. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.(9) Morris, J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.(10) U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. Last accessed: August 2024.(11) Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: August 2024.(12) The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: August 2024.(13) Pharmaceutical Technology. 2024. South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s. Last accessed: August 2024.(14) Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer’s treatment. Last accessed: August 2024.(15) BioSpace. 2024. Leqembi approved for the treatment of Alzheimer’s disease in Israel. Last accessed: August 2024.(16) United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: August 2024. Copyright 2024 JCN Newswire via SeaPRwire.com.

Toyota City, Japan, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - TOYOTA GAZOO Racing (TGR) began accepting orders today for the new GR Supra GT4 EVO2, for which vast feedback from racing teams and drivers around the world was leveraged to achieve higher levels of performance, reliability, and operability.Since the launch of the GR Supra GT4 in 2020, thanks to the support of race organizers and customers, cumulative sales(1) of the model have surpassed 120 units. The efforts of racing teams and drivers have enabled it to win GT4-series races and international races in 11 countries and regions, earn more than 500 podium finishes(2), and become the class champion in three regions: Asia, the United States, and Europe.An updated GR Supra GT4 EVO for the 2023 season featured improved braking, handling, and engine performance, making the car easier to drive for drivers of various skill levels. Yet, after that update, with there being no end to its efforts to make ever-better motorsports-bred cars, TGR continued to travel to race tracks around the world to directly receive valuable feedback from racing teams and drivers that can only be obtained under the extreme conditions of racing. Advancing its "driver-first car-making" approach for leveraging such insights into development, TGR has set the race debut of the GR Supra GT4 EVO2, with improved performance, reliability, and operability, at the start of the 2025 season.Specifically, ABS maps were meticulously re-tuned through driving by various drivers on circuits in Japan and Europe to enable optimal braking and cornering based on tire type and wear and the condition of the course. Additionally, downshifting time has been reduced by fine-tuning the rev matching through a software update, leading to enhanced deceleration control during braking for increased cornering speed. Also, in addition to improving the cooling performance of the engine, brakes, and drivetrain, cockpit temperatures have been optimized to make the car easier to drive even in harsh conditions, helping to maintain a high level of performance. These improvements make the GR Supra GT4 EVO2 easier to drive not only for professional racers but also for amateur drivers ambitiously competing in GT4 races worldwide.The GR Supra GT4 EVO2 is scheduled to make its world debut in January 2025 in the first round of the IMSA Michelin Pilot Challenge, held in conjunction with the 24 Hours of Daytona.GT4 sales and customer support (spare parts sales and technical support) will be handled by TOYOTA GAZOO Racing Europe GmbH in Europe, TRD U.S.A., Inc. in North America, Toyota Customizing and Development Co., Ltd. in Japan and other countries in Asia (excluding China), and Toyota Motor (China) Investment Co., Ltd. in China.(1) Including the GR Supra GT4 EVO(2) As of the end of July 2024For more information, visit https://global.toyota/en/newsroom/toyota/41393991.html. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI), together with Kirin Group companies Kirin Beverage Co., Ltd. and Kirin Group Logistics Co., Ltd., in August will begin a joint demonstration aimed at establishing elemental technologies for the automation of inbound and outbound processes at beverage warehouses, and the loading and unloading of trucks. The joint demonstration will be conducted at LogiQ X Lab, a demonstration facility located within Yokohama Hardtech Hub (YHH), MHI's co-creation space in Honmoku, Yokohama, and at Kirin Group Logistics sites. The demonstration is scheduled to conclude by March 2026.For this demonstration, as part of the "Smart Connections" solutions incorporating the ΣSynX (Sigma Syncs) technology(Note1) that MHI is currently researching and developing, MHI will utilize a new type of unmanned forklift that is currently under development equipped with ΣSynX, with the aim of establishing elemental technologies that enable flexible autonomous operation and safe human-machine coordination, including appropriate load assortment in warehouse work, altering of operational routes in response to changes in placement locations and storage conditions, and highly efficient storage methods. Through this joint demonstration, MHI aims for future automation of the entire cargo handling process, from the unloading of trucks to handling of inbound and outbound warehouses process, and loading onto trucks.MHI is steadily advancing efforts to utilize "Smart Connections" solutions incorporating the ΣSynX (Sigma Syncs) technology for automation and intelligence of normal logistics warehouse work, which up to now has been conducted safely and efficiently through the expertise, experience and skills of operators, focusing on the three areas of picking, inbound and outbound processes, and the loading and unloading of trucks. Following picking, which is the handling of cargo in warehouses, MHI will pursue development and verification to support the implementation of "Smart Connections" solutions for warehouse operations in the logistics industry. MHI and Kirin Group conducted a joint demonstration of automated picking from November 2022 to June 2023.(Note2) This demonstration verified its effectiveness at logistics sites, and an automated picking solution is scheduled to start operation at Kirin Group's Ebina Logistics Center in Kanagawa Prefecture from December 2024. This new joint demonstration being conducted by the two companies will accelerate the response to the challenges posed to the logistic industry by regulatory changes implemented in 2024.Going forward, through coordination with Kirin Group for this demonstration program, MHI will work to provide solutions for the various issues faced by the beverage industry due to regulatory changes, such as the shortage of logistics operators, the need for improvement in working conditions, and reducing truck driver working hours and wait times.(1) ΣSynX (Sigma Syncs) is MHI's standard platform for synchronizing and coordinating various types of machinery systems. It consolidates a host of digital technologies that enable optimized operation by making machinery systems intelligent. For more information, please refer to the following press release. www.mhi.com/news/23100501.html(2) For more information on the joint demonstration with Kirin Group for an automated picking solution, please refer to the following press release. www.mhi.com/news/22112101.html　Overview of the Joint DemonstrationImplementation period: August 2024, through March 2026Demonstration sites: MHI's LogiQ X Lab demonstration facility at Yokohama Hardtech Hub (YHH), MHI's demonstration facility at Kobe Shipyard, and Kirin Group Logistics facilities such as Nishi-Nagoya and Amagasaki.Content for the demonstration- Determining of operational processes, including manned work, assuming the introduction of warehouse inbound and outbound process solutions- Determining of operational processes, including manned work, assuming the introduction of unmanned forklifts for loading and unloading trucks- Determining of safety concepts, rules, operating conditions, and other standards for collaborative work with manned and unmanned forkliftsTags: Sigma SynX,Smart InfrastructureAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.